Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diquafosol - Merck/Santen Pharmaceutical

Drug Profile

Diquafosol - Merck/Santen Pharmaceutical

Alternative Names: DE-089; DE-089C; Diquafosol sodium; Diquafosol tetrasodium; Diquas; Diquas ophthalmic solution; INS 365; KPY 998; Prolacria; STN-1008903

Latest Information Update: 16 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Meiji Seika Pharma; Santen Pharmaceutical
  • Class Antibronchitics; Antifibrotics; Expectorants; Eye disorder therapies; Polyphosphates; Small molecules; Uracil nucleotides
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Corneal ulcer; Cystic fibrosis

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for phase-I development in Dry-eyes in Taiwan (Ophthalmic, Liquid)
  • 28 Aug 2020 Santen Pharmaceutical initiates a phase IIIb trial in Dry eyes in Japan (JapicCTI205466)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top